Day 1 – Tuesday, 16 September 2025Tuesday, September 16, 2025 - ET (Eastern Time, GMT-05:00)

Following a slow period for both M&A and IPO markets between 2022 and the first half of 2024 there has been a welcome uptick across both markets, bringing optimism and expectation to startups and investors alike. Our panel of medtech leaders and investors discuss the key factors in the return of medtech exits, what it means moving forward and strategies for companies effectively approaching exits.

• A review of the IPO and M&A markets over the past 12 months
• Expectations and trends for the next 18 months
• When and how companies should approach exit strategies

Amid a growing M&A market and better macroeconomic conditions, major strategics are deploying more capital and entering into more partnerships with smaller companies to drive growth. Hear from our mix of strategic business development and CVC executives to discuss best practice for engaging with these strategics as well as hearing their priorities and areas of focus over the next 12-18 months.

• The best time to approach strategics, and strategies for getting in front of decision makers
• Milestones strategic partners look for when considering partnership
• The areas major strategics are prioritising in the next 18 months

Women’s health has long been underserved in healthcare, in recent years the tide has turned with greater investment flowing into the sector. Now the companies at the forefront of women’s health are engaged in Series C and later funding rounds to truly scale and commercialize their technology. Our panel of women’s health executives discuss their experience and the investment landscape at greater scales.

• Challenges and trends within the women’s health space
• Women’s health investment landscape
• Market opportunities in women’s health

In an industry worth over $500B, and with near constant innovation, it is easy to lose sight of the macro trends within the sector. With general optimism returning to the space, some therapeutic areas could be poised for significant growth powered by an influx of funding. Hear from our panel of CEOs and medtech leaders on their priorities and challenges from operating in the hottest areas within the industry.

• Reviewing the “hottest” areas in medtech
• Focus areas for strategic investors and tier 1 BD teams
• The benefits and challenges of being an innovator in a competitive area

As the boundaries between medtech and digital health blur, AI and Software as a Medical Device (SaMD) are at the forefront of the techmed revolution. But innovation alone isn’t enough, success in this space depends on verifiable quality training data sources, regulatory adaptation, and investor confidence. This panel brings together techmed innovators, regulatory experts, and investors to explore how AI and SaMD are reshaping healthcare and where the biggest opportunities lie.

• Investor perspectives, how trust, ethics and cybersecurity impact investment in AI, SaMD and techmed
• Characteristics and importance of a good AI training dataset
• The role of the FDA in keeping up with and ensuring safety of new technologies

Regulatory approval continues to be an essential milestone in the commercialization of medtech products, it constitutes a big step in the de-risking of a medtech investment and proves the safety of medical technologies. Our panel discusses the importance of efficient and effective strategies in streamlining and maximising the opportunity the FDA presents.

• How reform under the Trump administration may alter the FDA workflow
• The importance of looking ahead to reimbursement opportunities in approval strategy
• Common pitfalls and challenges faced in the approval process

Despite the current tough fundraising landscape, venture capital remains the dominant source of investment in medtech and digital health. However, shifting dynamics are leading these companies to ask, “are VCs the only option for fundraising?” Our panel of investors and CEOs discuss emerging sources of funding from private equity and venture debt to government initiatives and strategic partnerships.

• Changes in funding models in recent years
• Expectations and milestones different sources of funding hold for their investments
• How companies in different stages of development can benefit from different funding sources

Funding is critical for medtech and digital health growth and commercialization, it is therefore essential for such companies to have a good understanding of investor expectations and a clear fundraising strategy when approaching investment opportunities. Our panel of investors discuss key milestones and qualities they look for from potential investments, and strategies for effectively communicating value in investor meetings.

• Priorities for investors in different stages of development
• How to build an effective investment strategy
• Strategies for successful investor communication